LENZ Therapeutics vs Voyager Therapeutics
LENZ and VYGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LENZ and VYGR compare
LENZ Therapeutics is the larger company, worth 1.2 times as much as Voyager Therapeutics ($130M against $107M).
LENZ Therapeutics grew revenue faster over the last twelve months (330% versus −19.8% for Voyager Therapeutics).
Voyager Therapeutics keeps more of each dollar of sales as profit, with a net margin of −416% compared with −587% at LENZ Therapeutics.
LENZ Therapeutics scores higher on the StockData Score (9 against 8 for Voyager Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LENZ | VYGR |
|---|---|---|
| Size and price | ||
| Market cap | $130M | $107M |
| Share price | $4.13 | $1.73 |
| Change, 1 year | −83.8% | −59.3% |
| Change, 5 years | −94.7% | −47.4% |
| Beta (5Y) | 1.08 | 1.19 |
| Employees | 152 | 141 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 3 | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.0× | 4.2× (better) |
| P/B | 0.6× (better) | 0.8× |
| FCF yield | −88.2% (better) | −103% |
| Fair value | $7.62 | $2.87 |
| Margin of safety | 45.8% (better) | 39.7% |
| Growth | ||
| Revenue growth (TTM) | 330% (better) | −19.8% |
| Revenue growth, 5Y average | – | −25.1% |
| Profitability | ||
| Operating margin | −632% | −450% (better) |
| Net margin | −587% | −416% (better) |
| FCF margin | −533% | −437% (better) |
| Return on equity | −59.2% | −58.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 13.55 (better) | 6.81 |
| Altman Z-score | 2.01 (better) | −3.91 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 110% | 56.9% |
| Held by insiders | 6.7% | 2.6% |
| Insider net buying, 12 months | −$8.8M | −$298K (better) |
| Short interest, % of float | 24.1% | 7.3% |
Go deeper
- LENZ stock overview
- LENZ income statement
- LENZ valuation and score
- VYGR stock overview
- VYGR income statement
- VYGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.